SO
SCLN

STRS Ohio’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

STRS Ohio’s Portfolio SCLN Stock Details SCLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-55,100
Closed -$550K – 1973
2016
Q4 		$595K Hold
55,100
– – ﹤0.01% 1276
2016
Q3 		$564K Sell
55,100
-2,100
-4% -$22.9K ﹤0.01% 1251
2016
Q2 		$747K Sell
57,200
-13,700
-19% -$180K ﹤0.01% 974
2016
Q1 		$779K Sell
70,900
-7,400
-9% -$65.8K ﹤0.01% 932
2015
Q4 		$720K Sell
78,300
-18,100
-19% -$152K ﹤0.01% 1013
2015
Q3 		$669K Buy
96,400
+14,700
+18% +$126K ﹤0.01% 1079
2015
Q2 		$802K Sell
81,700
-4,600
-5% -$41.9K ﹤0.01% 1019
2015
Q1 		$764K Sell
86,300
-2,200
-2% -$17.5K ﹤0.01% 967
2014
Q4 		$775K Sell
88,500
-10,000
-10% -$80.9K ﹤0.01% 960
2014
Q3 		$679K Sell
98,500
-35,600
-27% -$213K ﹤0.01% 998
2014
Q2 		$705K Sell
134,100
-7,100
-5% -$34.5K ﹤0.01% 1039
2014
Q1 		$642K Hold
141,200
– – ﹤0.01% 1053
2013
Q4 		$712K Sell
141,200
-16,300
-10% -$78.4K ﹤0.01% 1020
2013
Q3 		$799K Hold
157,500
– – ﹤0.01% 1003
2013
Q2 		$781K Buy
+157,500
New +$749K ﹤0.01% 1043

Other funds holding SCLN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

STRS Ohio's SCLN Position: Q1 2017 in Review

STRS Ohio sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q1 2017, closing a stake of 55,100 shares — an estimated $550K sold.

STRS Ohio first reported a position in SCLN in Q2 2013 and held it in 15 quarters. The position peaked at $802K in Q2 2015. 136 funds tracked by Wall St. Rank hold SCLN as of Q1 2017.

  • STRS Ohio reported no remaining Sciclone Pharmaceuticals Inc position as of Q1 2017 after selling out during the quarter.
  • STRS Ohio sold 55,100 Sciclone Pharmaceuticals Inc shares in Q1 2017, an estimated $550K.
  • STRS Ohio first reported a position in Sciclone Pharmaceuticals Inc in Q2 2013 and held it in 15 quarters.
  • STRS Ohio's Sciclone Pharmaceuticals Inc position peaked at $802K in Q2 2015.
  • 136 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q1 2017.

Based on STRS Ohio's 13F filing for Q1 2017, filed 26 Apr 2017.